Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients

Journal of Human Hypertension

Volumn 28, Issue 3, 2014, Pages 165-169

  Yoshida, S ^a   Takeuchi, T ^a   Kotani, T ^a   Yamamoto, N ^a   Hata, K ^a   Nagai, K ^a   Shoda, T ^a   Takai, S ^a   Makino, S ^a   Hanafusa, T ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

blood pressure; norepinephrine; renin angiotensin system; rheumatoid arthritis; tumour necrosis factor

Indexed keywords

ADRENALIN; C REACTIVE PROTEIN; DOPAMINE; INFLIXIMAB; NORADRENALIN; STROMELYSIN; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; RENIN; TUMOR NECROSIS FACTOR ALPHA;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; DISEASE ACTIVITY; DOPAMINE BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CIRCADIAN RHYTHM; DRUG EFFECTS; HYPERTENSION; MIDDLE AGED; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NOREPINEPHRINE; RENIN; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894091370     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.80     Document Type: Article

References (46)

1. Ozbalkan Z, Efe C, Cesur M, Ertek S, Nasiroglu N, Berneis K et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 2010;212:377-382.
2. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-1307.
3. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004;109:1955-1959.
4. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481-494.
5. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-2745.
6. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-2019.
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
8. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1477-1482.
9. Morrison A, Ramey DR, van Adelsberg J, Watson DJ. Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin 2007;23:2395-2404.
10. Rozman B, Praprotnik S, Logar D, Tomsic M, Hojnik M, Kos-Golja M et al. Leflunomide and hypertension. Ann Rheum Dis 2002;61:567-569.
11. Kvien TK, Zeidler HK, Hannonen P, Wollheim FA, Førre O, Hafström I et al. Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Ann Rheum Dis 2002;61:511-516.
12. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-1177.
13. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 2006;17:S218-S225.
14. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916.
15. Kim KI, Lee JH, Chang HJ, Cho YS, Youn TJ, Chung WY et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J 2008;72:293-298.
16. Dörffel Y, Lätsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmester GR et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999;34:113-117.
17. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999;84:272-278.
18. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rhuem 1993;36:1681-1690.
19. Elmarakby AA, Quigley JE, Pollock DM, Imig JD. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 2006;47:557-562.
20. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-a therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012;25:644-650.
21. Mäki-Petäjä KM, Elkhawad M, Cheriyan J, Joshi FR, Ostör AJ, Hall FC et al. Antitumor necrosis factor-a therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012;126:2473-2480.
22. Dulai R, Perry M, Twycross-Lewis R, Morrissey D, Atzeni F, Greenwald S. The effect of tumor necrosis factor-a antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin Arthritis Rheum 2012;42:1-8.
23. Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis 2010;69:1342-1345.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
25. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48.
26. Ferreri NR, Zhao Y, Takizawa H, McGiff JC. Tumor necrosis factor-alpha-angiotensin interactions and regulation of blood pressure. J Hypertens 1997;15:1481-1484.
27. Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1428-1432.
28. van der Steen MS, Lenders JW, Graafsma SJ, den Arend J, Thien T. Reproducibility of ambulatory blood pressure monitoring in daily practice. J Hum Hypertens 1999;13:303-308.
29. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003;107:1401-1406.
30. Ikeda T, Gomi T, Shibuya Y, Matsuo K, Kosugi T, Oku N et al. Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients. Hypertens Res 2004;27:939-946.
31. Kario K. Time for focus on morning hypertension: Pitfall of current antihypertensive medication. Am J Hypertens 2005;18:149-151.
32. Zakopoulos NA, Tsivgoulis G, Barlas G, Papamichael C, Spengos K, Manios E et al. Time rate of blood pressure variation is associated with increased common carotid artery intima-media thickness. Hypertension 2005;45:505-512.
33. Kaneda R, Kario K, Hoshide S, Umeda Y, Hoshide Y, Shimada K. Morning blood pressure hyper-reactivity is an independent predictor for hypertensive cardiac hypertrophy in a community-dwelling population. Am J Hypertens 2005;18:1528-1533.
34. Maeda K, Yasunari K, Watanabe T, Nakamura M. Oxidative stress by peripheral blood mononuclear cells is increased in hypertensives with an extreme-dipper pattern and/or morning surge in blood pressure. Hypertens Res 2005;28:755-761.
35. Marfella R, Siniscalchi M, Portoghese M, Di Filippo C, Ferraraccio F, Schiattarella C et al. Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque: role of ubiquitin-proteasome activity. Hypertension 2007;49:784-791.
36. Dixon WG, Watson KD, Lunt M, Hyrich KL. British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to antitumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-2912.
37. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-86.
38. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:868-872.
39. Furlan R, Guzzetti S, Crivellaro W, Dassi S, Tinelli M, Baselli G et al. Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. Circulation 1990;81:537-547.
40. Portaluppi F, Bagni B, degli Uberti E, Montanari L, Cavallini R, Trasforini G et al. Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjects. J Hypertens 1990;8:85-95.
41. Dodt C, Breckling U, Derad I, Fehm HL, Born J. Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. Hypertension 1997;30:71-76.
42. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med 1991;325:986-990.
43. Pickering TG, Levenstein M, Walmsley P. Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group. Am J Hypertens 1994;7:844-847.
44. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2004;43:169-175.
45. Takahashi H, Nishimura M, Sakamoto M, Ikegaki I, Nakanishi T, Yoshimura M. Effects of interleukin-1 beta on blood pressure, sympathetic nerve activity, anf pituitary endocrine functions in anesthetized rats. Am J Hypertens 1992;5:224-229.
46. Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis factoralpha in angiotension 2-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 2008;51:1345-1351.